| Propagation of tau pathology in a model of early Alzheimer's disease A De Calignon, M Polydoro, M Suárez-Calvet, C William, DH Adamowicz, ... Neuron 73 (4), 685-697, 2012 | 1606 | 2012 |
| TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis G Kleinberger, Y Yamanishi, M Suárez-Calvet, E Czirr, E Lohmann, ... Science translational medicine 6 (243), 243ra86-243ra86, 2014 | 816 | 2014 |
| sTREM 2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers M Suárez‐Calvet, G Kleinberger, MÁ Araque Caballero, M Brendel, ... EMBO molecular medicine 8 (5), 466-476, 2016 | 511 | 2016 |
| Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum AL Benedet, M Milà-Alomà, A Vrillon, NJ Ashton, TA Pascoal, F Lussier, ... JAMA neurology 78 (12), 1471-1483, 2021 | 357 | 2021 |
| Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ … M Suárez‐Calvet, TK Karikari, NJ Ashton, J Lantero Rodriguez, ... EMBO molecular medicine 12 (12), e12921, 2020 | 325 | 2020 |
| Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease M Milà-Alomà, NJ Ashton, M Shekari, G Salvadó, P Ortiz-Romero, ... Nature medicine 28 (9), 1797-1801, 2022 | 322 | 2022 |
| Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline J Lantero Rodriguez, TK Karikari, M Suárez-Calvet, C Troakes, A King, ... Acta neuropathologica 140, 267-278, 2020 | 298 | 2020 |
| Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative TK Karikari, AL Benedet, NJ Ashton, J Lantero Rodriguez, A Snellman, ... Molecular psychiatry 26 (2), 429-442, 2021 | 297 | 2021 |
| Early changes in CSF sTREM2 in dominantly inherited Alzheimer’s disease occur after amyloid deposition and neuronal injury M Suárez-Calvet, MÁ Araque Caballero, G Kleinberger, RJ Bateman, ... Science translational medicine 8 (369), 369ra178-369ra178, 2016 | 286 | 2016 |
| The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer’s disease risk Y Deming, F Filipello, F Cignarella, C Cantoni, S Hsu, R Mikesell, Z Li, ... Science translational medicine 11 (505), eaau2291, 2019 | 260 | 2019 |
| Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer’s disease M Ewers, N Franzmeier, M Suárez-Calvet, E Morenas-Rodriguez, ... Science translational medicine 11 (507), eaav6221, 2019 | 251 | 2019 |
| Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology M Suárez-Calvet, E Morenas-Rodríguez, G Kleinberger, K Schlepckow, ... Molecular neurodegeneration 14, 1-14, 2019 | 236 | 2019 |
| Longitudinal associations of blood phosphorylated Tau181 and neurofilament light chain with neurodegeneration in Alzheimer disease A Moscoso, MJ Grothe, NJ Ashton, TK Karikari, JL Rodríguez, A Snellman, ... JAMA neurology 78 (4), 396-406, 2021 | 227 | 2021 |
| Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility TK Karikari, NJ Ashton, G Brinkmalm, WS Brum, AL Benedet, ... Nature Reviews Neurology 18 (7), 400-418, 2022 | 209 | 2022 |
| The FTD‐like syndrome causing TREM 2 T66M mutation impairs microglia function, brain perfusion, and glucose metabolism G Kleinberger, M Brendel, E Mracsko, B Wefers, L Groeneweg, X Xiang, ... The EMBO journal 36 (13), 1837-1853, 2017 | 209 | 2017 |
| Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum A Moscoso, MJ Grothe, NJ Ashton, TK Karikari, JL Rodriguez, A Snellman, ... Brain 144 (1), 325-339, 2021 | 204 | 2021 |
| Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum M Milà‐Alomà, G Salvadó, JD Gispert, N Vilor‐Tejedor, O Grau‐Rivera, ... Alzheimer's & Dementia 16 (10), 1358-1371, 2020 | 185 | 2020 |
| An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders NJ Ashton, A Hye, AP Rajkumar, A Leuzy, S Snowden, M Suárez-Calvet, ... Nature Reviews Neurology 16 (5), 265-284, 2020 | 180 | 2020 |
| Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes N Setó-Salvia, J Clarimón, J Pagonabarraga, B Pascual-Sedano, ... Archives of neurology 68 (3), 359-364, 2011 | 178 | 2011 |
| Tau enhances α-synuclein aggregation and toxicity in cellular models of synucleinopathy N Badiola, RM de Oliveira, F Herrera, C Guardia-Laguarta, SA Goncalves, ... PloS one 6 (10), e26609, 2011 | 172 | 2011 |
Juan Domingo GispertImaging Scientist. Director of Clinical Imaging - Early Clinical Development at AstraZenecaVerificeret mail på barcelonabeta.org